. He can be reached at nsaraceno@mjhlifesciences.com.

Articles

A survey study takes a closer look into which medications patients would like to have deprescribed, along with the reasons and factors influencing that decision.

Reducing Polypharmacy in Older Adults

Videos

In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Jody Hatcher, CEO of Morris & Dickson and chair of HDA’s board of directors, outlines the implications that potential 25% tariffs on pharmaceuticals could have, as far as manufacturers reshoring their production services are concerned.

The Impact of Pharma Tariffs on Drug Shortages

Pharma Pulse 4/22/25: FDA Moves to Block Biopharma Employees From Serving on Advisory Committees, FDA Cuts Outlined in Draft HHS Budget

The Carlsbad plant is expected to accelerate both the development and commercialization of cell therapies. 

Thermo Fisher Scientific Unveils Advanced Therapies Collaboration Center 

In the third part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Jody Hatcher, CEO of Morris & Dickson and chair of HDA’s board of directors, comments on the steps needed to achieve Drug Supply Chain Security Act compliance.

Preparing for DSCSA Deadlines 

Pharma Pulse 4/21/25: Using AI to Predict Launch Success, A Pharmacist’s Guide to Blockbuster Patent Expirations: 2025 and Beyond

By embracing practical, human-centered use cases, life sciences companies are breaking free from GenAI “pilotitis” and demonstrating how scalable AI solutions can help transform patient care and provider efficiency.

Innovation with GenAI: Lessons from Life Sciences and Beyond

In the second part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Jody Hatcher, CEO of Morris & Dickson and chair of HDA’s board of directors, describes his day-to-day workflow at Morris & Dickson, and how it supports the efficiency and reliability of the distributor’s operations.

The Quest to Deliver Reliability

Pharma Pulse 4/18/25: Bringing Biotech Innovation Across Borders, Role of Collaboration in Advancing Rare Disease Research

Will Robinson, program director, LogiPharma, shares how in-depth conversations—not AI—drive the research behind one of the industry's most anticipated annual agendas.

News